for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amphastar Pharmaceuticals Inc

AMPH.OQ

Latest Trade

18.12USD

Change

0.25(+1.40%)

Volume

75,839

Today's Range

17.51

 - 

18.34

52 Week Range

12.32

 - 

22.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.87
Open
17.51
Volume
75,839
3M AVG Volume
4.09
Today's High
18.34
Today's Low
17.51
52 Week High
22.69
52 Week Low
12.32
Shares Out (MIL)
47.50
Market Cap (MIL)
848.90
Forward P/E
29.62
Dividend (Yield %)
--

Next Event

Amphastar Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Amphastar Pharmaceuticals Reports Q3 EPS Of $0.08

Amphastar Pharmaceuticals Receives FDA Approval For Atropine Sulfate Injection

Amphastar Pharmaceuticals Reports Q2 Flat GAAP Earnings

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Industry

Biotechnology & Drugs

Contact Info

11570 6th St

RANCHO CUCAMONGA, CA

91730-6025

United States

+1.909.9809484

http://www.amphastar.com

Executive Leadership

Mary Ziping Luo

Chief Operating Officer, Chief Scientist and Chairman of the Board

Jack Yongfeng Zhang

President, Chief Executive Officer, Chief Scientific Officer, Director

William J. Peters

Chief Financial Officer, Senior Vice President, Treasurer and President of International Medication Systems, Limited

Rong Zhou

Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc.

Jacob Liawatidewi

Senior Vice President of Sales and Marketing, Corporate Administration Center, Corporate Secretary

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.3K

2019

0.3K

2020(E)

0.3K
EPS (USD)

2017

0.380

2018

0.210

2019

0.360

2020(E)

0.603
Price To Earnings (TTM)
132.91
Price To Sales (TTM)
2.52
Price To Book (MRQ)
2.10
Price To Cash Flow (TTM)
30.14
Total Debt To Equity (MRQ)
11.12
LT Debt To Equity (MRQ)
8.12
Return on Investment (TTM)
1.65
Return on Equity (TTM)
1.27

Latest News

Latest News

BRIEF-Amphastar Pharmaceuticals gets FDA Approval For Epinephrine Injection

* AMPHASTAR PHARMACEUTICALS, INC. RECEIVES FDA APPROVAL FOR EPINEPHRINE INJECTION, USP 30MG/30ML (1MG/ML) MULTIPLE DOSE VIAL

BRIEF-Amphastar Pharmaceuticals Inc Simplifies Management Structure

* AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SIMPLIFICATION OF MANAGEMENT STRUCTURE

BRIEF-Amphastar Pharmaceuticals Reports Q4 Revenue Of $83.4 Mln

* AMPHASTAR PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS AND FULL YEAR ENDED DECEMBER 31, 2019

BRIEF-Amphastar Pharmaceuticals Receives FDA Approval For Supplement To Its Abbreviated New Drug Application For Sodium Bicarbonate Injection

* AMPHASTAR PHARMACEUTICALS RECEIVES FDA APPROVAL FOR SUPPLEMENT TO ITS ABBREVIATED NEW DRUG APPLICATION FOR SODIUM BICARBONATE INJECTION, USP 8.4%, 50MEQ/50ML Source text for Eikon: Further company coverage:

Momenta, Amphastar settle generic Lovenox drug patent case

Amphastar Pharmaceuticals Inc on Wednesday said Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit will pay it $59.9 million to resolve patent and antitrust lawsuits over their dueling generic versions of the blood-thinner Lovenox.

BRIEF-Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz

* AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ

Amphastar cannot collect $100 mln during Momenta drug patent appeal - judge

A federal judge on Monday ruled that Amphastar Pharmaceuticals Inc must wait to collect a $100 million bond that Momenta Pharmaceuticals Inc and Sandoz Inc posted in a drug patent case it won until after an appellate court hears the dispute.

BRIEF-Amphastar Pharmaceuticals Receives FDA Approval For Calcium Chloride Injection

* AMPHASTAR PHARMACEUTICALS RECEIVES FDA APPROVAL FOR CALCIUM CHLORIDE INJECTION

BRIEF-Amphastar Announces Approval For Sodium Nitroprusside Injection, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION, USP

BRIEF-Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up